VIDEO: Immunosuppressives may negate anti-drug antibody development from pegloticase

In this video, Craig A. Shadur, MD, a transplant nephrologist from Des Moines, Iowa, discussed the use of pegloticase for patients with kidney transplants.

The study, presented as part of ASN Kidney Week, looked at the efficacy of pegloticase, which in non-transplant patients, has the potential for development of anti-drug antibodies, Shadur said.

“What struck me was that in the transplant setting, we virtually didn't see this with patients that were treated,” Shadur said.

Using a database, investigators identified approximately 91 patients who received pegloticase for treatment of gout in a 5-year period.

“We found that these patients were treated with multiple doses of pegloticase, indicating that they were not developing antibodies and also indicating that the immunosuppressive drugs they were on presumably negated the production of anti-drug antibodies,” he said.